It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The kidney’s inherent complexity has made identifying cell-specific pathways challenging, particularly when temporally associating them with the dynamic pathophysiology of acute kidney injury (AKI). Here, we combine renal cell-specific luciferase reporter mice using a chemoselective luciferin to guide the acquisition of cell-specific transcriptional changes in C57BL/6 background mice. Hydrogen peroxide generation, a common mechanism of tissue damage, was tracked using a peroxy-caged-luciferin to identify optimum time points for immunoprecipitation of labeled ribosomes for RNA-sequencing. Together, these tools revealed a profound impact of AKI on mitochondrial pathways in the collecting duct. In fact, targeting the mitochondria with an antioxidant, ameliorated not only hydrogen peroxide generation, but also significantly reduced oxidative stress and the expression of the AKI biomarker, LCN2. This integrative approach of coupling physiological imaging with transcriptomics and drug testing revealed how the collecting duct responds to AKI and opens new venues for cell-specific predictive monitoring and treatment.
Miyazaki, Gharib, Hsu et al. use a combined cell-specific luciferase reporter system and chemo-selective substrate to identify mouse tissues at risk of renal injury. The platform can be used to identify cell-specific pathophysiological events and transcriptional changes, finding potential therapeutic targets.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Washington, Division of Nephrology, Department of Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); Showa University, Division of Nephrology, Department of Medicine, Yokohama, Japan (GRID:grid.410714.7) (ISNI:0000 0000 8864 3422)
2 University of Washington, Computational Medicine Core, Center for Lung Biology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
3 University of Washington, Division of Nephrology, Department of Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
4 Columbia University, Renal Division, Department of Medicine, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
5 Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne (EPFL), Lausanne, Switzerland (GRID:grid.5333.6) (ISNI:0000000121839049)
6 Lawrence Livermore Labs, Livermore, USA (GRID:grid.34477.33)
7 InVivo Analytics, Inc., New York, USA (GRID:grid.504638.c)
8 PerkinElmer, Inc., Hopkinton, USA (GRID:grid.419236.b) (ISNI:0000 0001 2176 1341)
9 Vanderbilt University Medical Center, Division of Nephrology, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)